Compare MPLT & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPLT | BHVN |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | 133 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | 2022 |
| Metric | MPLT | BHVN |
|---|---|---|
| Price | $28.57 | $9.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $32.67 | $29.08 |
| AVG Volume (30 Days) | 253.4K | ★ 1.7M |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.24 | $7.48 |
| 52 Week High | $33.28 | $18.57 |
| Indicator | MPLT | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 51.14 |
| Support Level | $26.70 | $9.26 |
| Resistance Level | $32.23 | $10.57 |
| Average True Range (ATR) | 2.34 | 0.66 |
| MACD | -0.40 | 0.00 |
| Stochastic Oscillator | 58.24 | 49.41 |
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.